European Heart Journal Advance Access originally published online on September 4, 2006
European Heart Journal 2006 27(19):2353-2361; doi:10.1093/eurheartj/ehl233
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation
Department of Cardiology, Castle Hill Hospital, Cottingham, Kingston-upon-Hull HU16 5JQ, UK
Received 7 February 2006; revised 11 July 2006; accepted 17 August 2006; online publish-ahead-of-print 4 September 2006.
* Corresponding author. Tel: +44 1482 624073; fax: +44 7902 840055. E-mail address: rhidianshelton{at}btopenworld.com
Aims To assess the role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the diagnosis of major structural heart disease (MSHD) in patients with atrial fibrillation (AF) compared with those with sinus rhythm (SR) using receiver operator characteristic (ROC) analysis. NT-proBNP is elevated in MSHD and heart failure (HF). AF, a common finding in HF and MSHD, is also associated with raised plasma NT-proBNP. As a result, the utility of NT-proBNP for predicting MSHD may be reduced.
Methods and results One thousand four hundred and seventy-six patients underwent assessment at a single centre, performed without the knowledge of NT-proBNP levels. MSHD included left ventricular (LV) systolic and diastolic dysfunctions, left-sided valvular disease, right heart disease (including pulmonary hypertension) and severe LV hypertrophy. One hundred and fifty-five patients were excluded due to renal impairment, atrial flutter, or a pacemaker. Seven hundred and ninety-three patients were diagnosed with MSHD. Median NT-proBNP concentrations for patients with MSHD were 960 (IQR 359–2625) pg/mL and 2491 (1443–4368) pg/mL for SR (n=591) and AF (n=202), respectively (P<0.001). Patients without MSHD had NT-proBNP levels of 179 (90–401) pg/mL and 1000 (659–1760) pg/mL for SR (n=454) and AF (n=74), respectively (P<0.001). The area under the ROC curve for NT-proBNP to detect MSHD was 0.79 for SR (95% CI 0.77–0.82) and 0.78 for AF (95% CI 0.72–0.84). NT-proBNP cut-off levels necessary to achieve a 1 in 100 false negative rate were 27.5 (7.5–30.5) pg/ml and 524 (253–662) pg/ml for SR and AF, respectively.
Conclusion NT-proBNP performs as well in patients with SR as in those with AF. However, significantly higher cut-off levels are required for patients with AF to achieve similar levels of diagnostic specificity.
Key Words: Atrial fibrillation • Heart failure • Natriuretic peptides
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. K. Patton, P. T. Ellinor, S. R. Heckbert, R. H. Christenson, C. DeFilippi, J. S. Gottdiener, and R. A. Kronmal N-Terminal Pro-B-Type Natriuretic Peptide Is a Major Predictor of the Development of Atrial Fibrillation: The Cardiovascular Health Study Circulation, November 3, 2009; 120(18): 1768 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Schou, U Alehagen, J P Goetze, F Gustafsson, and U Dahlstrom Effect of estimated glomerular filtration rate on plasma concentrations of B-type natriuretic peptides measured with multiple immunoassays in elderly individuals Heart, September 15, 2009; 95(18): 1514 - 1519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bukowska, U. Lendeckel, A. Krohn, G. Keilhoff, S. t. Have, K. H. Neumann, and A. Goette Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney Europace, October 1, 2008; 10(10): 1212 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maisel, C. Mueller, K. Adams Jr., S. D. Anker, N. Aspromonte, J. G.F. Cleland, A. Cohen-Solal, U. Dahlstrom, A. DeMaria, S. Di Somma, et al. State of the art: Using natriuretic peptide levels in clinical practice Eur J Heart Fail, September 1, 2008; 10(9): 824 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Ingle, J G F Cleland, and A L Clark Perception of symptoms is out of proportion to cardiac pathology in patients with "diastolic heart failure" Heart, June 1, 2008; 94(6): 748 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Freestone, F. Gustafsson, A. Y. Chong, P. Corell, C. Kistorp, P. Hildebrandt, and G. Y. H. Lip Influence of Atrial Fibrillation on Plasma Von Willebrand Factor, Soluble E-Selectin, and N-Terminal Pro B-type Natriuretic Peptide Levels in Systolic Heart Failure Chest, May 1, 2008; 133(5): 1203 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nieuwlaat, L. W. Eurlings, A. Capucci, and H. J.G.M. Crijns Atrial fibrillation in the 'real world': undecided issues Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I122 - I128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Olsson, K. Swedberg, J. G.F. Cleland, P. A. Spark, M. Komajda, M. Metra, C. Torp-Pedersen, W. J. Remme, A. Scherhag, P. Poole-Wilson, et al. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a {beta}-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial Eur J Heart Fail, August 1, 2007; 9(8): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, R. Shelton, N. Nikitin, S. Ford, L. Frison, and M. Grind Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: A report from the SPORTIF III and V trials Eur J Heart Fail, June 1, 2007; 9(6-7): 730 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rienstra, I. C. Van Gelder, M. P. Van den Berg, and D. J. Van Veldhuisen Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP: reply Europace, February 1, 2007; 9(2): 148 - 148. [Full Text] [PDF]
|
|